# Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

Source: https://onco.cc/trials/nct07509008/  
OnCo record `nct07509008` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.

## Summary

The registry lists NCT07509008 as not yet recruiting, last updated 2026-07-29. Enrolment is 10 planned participants, an estimate. Interventions: TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine, Cyclophosphamide. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Registry id: NCT07509008
- Phase: 1/2
- Setting: Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
- Sponsor: M.D. Anderson Cancer Center

## Sources

- ClinicalTrials.gov NCT07509008: https://clinicaltrials.gov/study/NCT07509008

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/nct07509008.json